

AirInSpace in the News! Increasing pandemic concerns motivate hospitals and health authorities to implement state-of-the-art infection control solutions

AirInSpace, leader in mobile air-decontamination devices for hospitals, accelerate its penetration of the hospital market with innovative solutions that meet the increasing infection control challenges facing today's healthcare establishments. AirInSpace builds on its unique non-thermal plasma-based technology, HEPA-MD™ that **captures and destroys airborne pathogens.**



The HEPA-MD™ technology is used in a mobile air purifier/recirculating air cleaner called **Plasmair™**. This device is an FDA approved medical device (510K K070722) for filtering out and inactivating airborne particles from the air for medical purposes. This clinically tested device is currently being successfully used worldwide in hospitals to create environments that protect patients from airborne infection risks.

Today AirInSpace, by using over seven years of accumulated testing and experience can provide hospitals with the capability to transform standard rooms into highly protected environments nearly instantaneously.

Over the past few days French National Television has highlighted two applications that showcase AirInSpace's technology:

1. Preventing the spread of a pandemic flu: Creation of protected zones for suspect cases of H1N1

The Department for Infectious Diseases at the University Hospital in Montpellier, France, has decided to use the company's flagship product Plasmair™ in their hospital for screening and housing suspected and confirmed H1N1 patients (See the website <http://videos.tf1.fr/jt-13h/le-13-heures-du-30-avril-2009-4399041.html> aired by the French national Television TF1, on April 30, 2009). Successful implementation of Plasmair as part of pandemic flu measures was recently underscored in the medical technology journal, Clinica, May 20, 2009.

The technology has been **validated to completely eradicate the airborne flu virus H5N2, a surrogate for H1N1** showing that the system completely destroys the current flu virus(es) of concern. These tests were carried out by the WHO flu specialist Dr. Bruno Lina to verify the efficiency of AirInSpace's technology in preparation for potential pandemic flu outbreaks.

Scientific Director, Dr. Vance Bergeron notes, "Recent findings from the Harvard School of Public Health and the Mont Sinai School of Medicine show that infection from airborne sources, even at long distances, can be important. AirInSpace's technology directly addresses this concern and has accumulated evidence-based clinical data that show that the Plasmair™ can significantly reduce the risk of infection from these types of airborne contaminants".

Relevant to the current situation, Dr. Annie Chalfine, Hygienist at Saint-Joseph Hospital in Paris, France, has developed a **strategy** for using the mobile Plasmair device to create protected sectors in the hospital in case of a **pandemic situation**. (videolink http://www.airinspace.com/fr/media_film.php).

Laurent Fullana, AirInSpace CEO, estimates that Plasmair™ can become a critical component in a national plan to manage pandemic threats. Plasmair does not only offer a cost effective alternative to negative pressure rooms but also can be effective at several critical points in the system: triage, waiting rooms, ICU cubicals, conventional areas hosting/treating high viral density populations. Moreover, these units offer value in protected environments during non pandemic times 'It is like buying an insurance policy for - hopefully – worst case scenario, and getting dividends at the same time' says Laurent Fullana.

2. Protective environments for children with acute leukemia after stem cell transplantation:

Children with acute leukemia face a life-threatening illness, and the work conducted at the Robert Debré hospital in Paris, France, is offering new hope. Here, groundbreaking treatment through the transplantation of stem cells extracted from the umbilical cord is providing children with a new lease on life. However, to make this work, patients must be placed under severe immune-suppression so their immune system doesn't reject the transplant – placing them at **high risk of infection**. Here is where AirInSpace makes a difference with the novel Immunair™ ISO protective environment. Immune-suppressed children placed under the Immunair™ ISO environment are protected from airborne contamination and they can also maintain direct contact with their parents and loved ones. Heightened awareness of healthcare professionals towards the importance of such air decontamination systems provided by a AirInSpace is witnessed on the French national Television TF1, aired on May 16, 2009: http://www.wat.tv/video/aujourd-hui-majorite-enfants-1i5zp_1eitl_.html.

Protected environments such as hematology and oncology wards have fueled AirInSpace's recent growth in its home market. The company has penetrated more than 75% of hematology centers and has started to expand its range of solutions with stationary devices called Biocair, also using AirInSpace HEPA MD destruction technology. A state-of-the-art oncology center in Poitiers University Hospital showcasing these Biocair Units was inaugurated last month by the French Ministry of Health Roselyne Bachelot.

About Airinspace:

Founded in 2002, Airinspace offers an innovative range of products and services to address the need for microbial decontamination of air in hospitals and other environments. For more information, please visit www.airinspace.com, or contact Airinspace directly at: mail@airinspace.com.